Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sapacitabine + Cyclophosphamide + Rituximab in Relapsed CLL/SLL
NCT01253460Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2011
- Primary completion
- Mar 2018
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of sapacitabine in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2011; status: terminated.
02
Drugs
sapacitabine
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT01253460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01253460.